20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Avalyn Pharma Inc. Common Stock (AVLN) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 55 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, AVLN reported $0M in revenue and ($85M) in net income.
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | $0M | $0M | $0M |
| Operating Income (EBIT) | ($100M) | ($91M) | ($57M) |
| Operating Margin % | — | — | — |
| Net Income | ($93M) | ($85M) | ($50M) |
| Net Margin % | — | — | — |
| EBITDA | — | ($91M) | — |
| Earnings Per Share (EPS) | — | $-2.04 | $-1.19 |
| Shares Outstanding (M) | 44M | 42M | 42M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($31M) | ($28M) | ($22M) | ($19M) |
| Operating Margin % | — | — | — | — |
| Net Income | ($29M) | ($27M) | ($20M) | ($18M) |
| Net Margin % | — | — | — | — |
| EBITDA | ($31M) | ($27M) | — | — |
| Earnings Per Share (EPS) | $-0.65 | $-0.64 | — | — |
| Shares Outstanding (M) | 44M | 42M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($96M) | ($81M) | ($48M) |
| Capital Expenditures (CapEx) | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($97M) | ($82M) | ($48M) |
| FCF Margin % | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($26M) | ($30M) | ($21M) | ($19M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($26M) | ($30M) | ($21M) | ($19M) |
| FCF Margin % | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets | $425M | $149M | $125M |
| Cash & Cash Equivalents | $264M | $52M | $24M |
| Total Liabilities | $27M | $388M | $299M |
| Total Debt (Short + Long-Term) | $16M | $0M | $0M |
| Total Shareholders' Equity | $398M | ($239M) | ($175M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AVLN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms